An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study


Eldem B., Lai T. Y. Y. , Ngah N. F. , Vote B., Yu H. G. , Fabre A., ...Daha Fazla

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, cilt.256, ss.963-973, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 256 Konu: 5
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1007/s00417-017-3890-8
  • Dergi Adı: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
  • Sayfa Sayıları: ss.963-973

Özet

To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia-Pacific region.